Horizon Pharma Inc. (NASDAQ:HZNP) shares saw strong trading volume on Wednesday . 3,727,033 shares were traded during trading, a decline of 18% from the previous session’s volume of 4,545,162 shares.The stock last traded at $17.29 and had previously closed at $16.72.

Several equities analysts have recently issued reports on the company. Vetr upgraded Horizon Pharma from a “hold” rating to a “buy” rating and set a $19.82 price objective for the company in a research report on Tuesday, June 7th. TheStreet upgraded Horizon Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, March 10th. Goldman Sachs Group Inc. assumed coverage on Horizon Pharma in a research report on Monday, June 6th. They set a “buy” rating and a $24.00 price objective for the company. Stifel Nicolaus reiterated a “buy” rating and set a $45.00 price objective on shares of Horizon Pharma in a research report on Wednesday. Finally, Cowen and Company reiterated a “buy” rating on shares of Horizon Pharma in a research report on Saturday, April 2nd. Two analysts have rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $29.93.

The firm has a market cap of $2.81 billion and a PE ratio of 227.40. The stock’s 50 day moving average is $16.85 and its 200 day moving average is $17.12.

Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported $0.34 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.30 by $0.04. The business earned $204.70 million during the quarter, compared to analyst estimates of $197.73 million. The company’s revenue was up 80.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.18 earnings per share. Equities research analysts anticipate that Horizon Pharma Inc. will post $2.35 earnings per share for the current fiscal year.

In other news, Director Virinder Nohria sold 25,000 shares of the stock in a transaction on Wednesday, June 15th. The shares were sold at an average price of $17.69, for a total transaction of $442,250.00. Following the completion of the sale, the director now directly owns 189,836 shares in the company, valued at $3,358,198.84. The transaction was disclosed in a filing with the SEC, which is available at this link.

Other large investors have recently bought and sold shares of the company. Systematic Financial Management LP boosted its stake in Horizon Pharma by 100.4% in the fourth quarter. Systematic Financial Management LP now owns 152,340 shares of the biopharmaceutical company’s stock valued at $3,301,000 after buying an additional 76,335 shares during the period. Zweig DiMenna Associates LLC boosted its stake in Horizon Pharma by 1,466.9% in the fourth quarter. Zweig DiMenna Associates LLC now owns 433,250 shares of the biopharmaceutical company’s stock valued at $9,389,000 after buying an additional 405,600 shares during the period. Deere & Co. purchased a new stake in Horizon Pharma during the fourth quarter valued at $1,873,000. Morgan Stanley boosted its stake in Horizon Pharma by 51.3% in the fourth quarter. Morgan Stanley now owns 548,234 shares of the biopharmaceutical company’s stock valued at $11,881,000 after buying an additional 185,829 shares during the period. Finally, Tekla Capital Management LLC boosted its stake in Horizon Pharma by 130.2% in the fourth quarter. Tekla Capital Management LLC now owns 749,900 shares of the biopharmaceutical company’s stock valued at $16,250,000 after buying an additional 424,100 shares during the period.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.